OLDWICK, N.J. , Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming conferences: The 9 th Annual SVB Leerink Global Healthcare Conference on Wednes
OLDWICK, N.J., Feb. 19, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at two upcoming conferences:
Each presentation will be webcast live and can be accessed by visiting the Events and Webcasts section of the Company’s website: http://investors.proventionbio.com/events. Each webcast will be archived on the Company’s website for 90 days following the presentation. About Provention Bio, Inc. Provention Bio, Inc. (Nasdaq: PRVB) is a clinical-stage biopharmaceutical company leveraging a transformational drug development strategy that is focused on the prevention or interception of immune-mediated disease. Provention’s mission is to in-license, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases including: type 1 diabetes (T1D), celiac disease and lupus. Provention’s diversified portfolio includes advanced-stage product development candidates that have undergone clinical testing by other companies. Investors: Media: View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-present-at-upcoming-conferences-301006966.html SOURCE Provention Bio, Inc. | ||
Company Codes: NASDAQ-NMS:PRVB |